CL2019003153A1 - Métodos para el tratamiento del síndrome de alport. - Google Patents

Métodos para el tratamiento del síndrome de alport.

Info

Publication number
CL2019003153A1
CL2019003153A1 CL2019003153A CL2019003153A CL2019003153A1 CL 2019003153 A1 CL2019003153 A1 CL 2019003153A1 CL 2019003153 A CL2019003153 A CL 2019003153A CL 2019003153 A CL2019003153 A CL 2019003153A CL 2019003153 A1 CL2019003153 A1 CL 2019003153A1
Authority
CL
Chile
Prior art keywords
alport syndrome
modified oligonucleotide
mir
treatment
methods
Prior art date
Application number
CL2019003153A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Wright
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2019003153A1 publication Critical patent/CL2019003153A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL2019003153A 2017-05-04 2019-11-04 Métodos para el tratamiento del síndrome de alport. CL2019003153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762501699P 2017-05-04 2017-05-04

Publications (1)

Publication Number Publication Date
CL2019003153A1 true CL2019003153A1 (es) 2020-03-27

Family

ID=62223298

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003153A CL2019003153A1 (es) 2017-05-04 2019-11-04 Métodos para el tratamiento del síndrome de alport.

Country Status (13)

Country Link
US (3) US20210100828A1 (enExample)
EP (1) EP3618838A1 (enExample)
JP (2) JP2020518633A (enExample)
KR (1) KR20190141770A (enExample)
CN (2) CN116585344A (enExample)
AU (1) AU2018261792A1 (enExample)
BR (1) BR112019022824A2 (enExample)
CA (1) CA3062316A1 (enExample)
CL (1) CL2019003153A1 (enExample)
MA (1) MA50749A (enExample)
MX (1) MX2019013158A (enExample)
SG (1) SG11201910099WA (enExample)
WO (1) WO2018204788A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076452A1 (en) * 2020-10-05 2022-04-14 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN120731923B (zh) * 2025-09-05 2025-11-04 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152700A1 (en) * 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
KR101877698B1 (ko) * 2008-08-25 2018-07-12 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
EP2825648B1 (en) * 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
BR112014026639A8 (pt) * 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
GB201507926D0 (en) * 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides

Also Published As

Publication number Publication date
US20240115598A1 (en) 2024-04-11
CN110740737A (zh) 2020-01-31
WO2018204788A1 (en) 2018-11-08
EP3618838A1 (en) 2020-03-11
CN116585344A (zh) 2023-08-15
JP2020518633A (ja) 2020-06-25
SG11201910099WA (en) 2019-11-28
RU2019139261A3 (enExample) 2021-09-06
KR20190141770A (ko) 2019-12-24
CA3062316A1 (en) 2018-11-08
AU2018261792A1 (en) 2020-01-02
RU2019139261A (ru) 2021-06-04
BR112019022824A2 (pt) 2020-06-09
US20210100828A1 (en) 2021-04-08
MX2019013158A (es) 2020-02-07
MA50749A (fr) 2020-03-11
JP2023075111A (ja) 2023-05-30
US20220133769A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
UY35069A (es) Métodos para el tratamiento del síndrome de alport
MX388743B (es) Conjugados oligonucleótido-péptido.
MX2017011638A (es) Dispositivos magnéticos de anastomosis con fuerza magnética variada a una distancia.
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
HK1246180A1 (zh) 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
CL2019003153A1 (es) Métodos para el tratamiento del síndrome de alport.
AR128192A2 (es) Métodos para el tratamiento del síndrome de alport
AR119688A2 (es) Métodos para el tratamiento del síndrome de alport
Standish Social justice and the Occident
EP3517542A4 (en) AGAINST DENDRITIC CELLS PEPTIDE, FUSION PEPTIDE WITH THIS PEPTID AND VACCINE WITH THIS FUSION PEPTIDE
NI201600061A (es) Formulaciones de inyección con base en aceite de sésamo
EA201791442A1 (ru) Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров
Sinha et al. Targeted ExSeq--Tissue Preparation
EA202191503A1 (ru) Комбинированные терапии для мдс высокого и очень высокого риска
郑征 Photo News
高妙男 Report on CE Translation of Gsm Enterprise Website
姚卓丹 Reflective Nationalism: A Study on Post-National Identity in the Untouchable
李煜 An Analysis of Apologies in American Sitcom The BIG Bang Theory from The Perspective of Politeness Principle
杨甜甜 A Study on Ec Auto News Trans-editing Based on Text Typology Theory
谢雨轩 Man of Rebellious Spirit: A Study of the Revolt Theme in James Joyce's Dubliners
მარიამ გაბისონია et al. ინტერვიუ
钱英英 A Study on CE Translation of Public Signs in Urumqi from The Perspective of Eco-translatology
石闻熙 Tuhao, Let's Make Friends!
杨春芝 On The Translation of Chinese Culture-loaded Words in Chinese American Literature